Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Sulfasalazine may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for The active substance in Salazopyrin Tablets is sulfasalazine which is an antiinflammatory drug and belongs to a group of medicines called aminosalicylates. Your doctor may give you Salazopyrin Tablets to treat and manage inflammatory bowel disease. Inflammatory bowel disease The main forms of inflammatory bowel disease are Ulcerative Colitis and Crohn's disease. Although the diseases have some features in common, there are some important differences. Ulcerative Colitis is an inflammatory disease which affects only the large bow el (colon and back passage). The lining of the bowel becomes inflamed (red and swollen) and symptoms include abdominal pain and diarrhoea (which may contain blood and mucus). Salazopyrin Tablets are used to control the flare-ups of ulcerative colitis. They may also be used at lower doses to prevent more flare-ups of ulcerative colitis. Crohn's disease is an inflammatory disease which may affect any part of the digestive system from the mouth to the anus, but it most commonly affects the last part of the small bowel and the first part of the large bowel. Symptoms include abdominal pain and diarrhoea (which may be bloody). Salazopyrin Tablets are used to control the flare-ups of Crohn's Disease. You must talk to a doctor if you do not feel better or if you feel worse.
Page 1 of 9
e Salazopyrin Tablets Your doctor will perform complete blood counts and liver function tests before starting Salazopyrin and every second week during the first three months of therapy. During the second three months, the same tests should be done once monthly and thereafter once every three months, and as clinically indicated. Urine analysis and an assessment of kidney function should also be done in all patients initiating treatment with Salazopyrin. For patients with baseline renal impairment, treatment with Salazopyrin should only be initiated if the benefits are considered to outweigh risk. Thereafter, periodic renal function monitoring, especially in the early months of treatment, should be conducted by your doctor during treatment with Salazopyrin. Treatment should be discontinued if renal function deteriorates. Do not take Salazopyrin Tablets:
Page 2 of 9
Potentially life-threatening skin rashes (exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported with the use of Salazopyrin Tablets, appearing initially as reddish target-like spots or circular patches often with central blisters on the trunk. Additional signs to look for include ulcers in the mouth, throat, nose, genitals and conjunctivitis (red and swollen eyes). These potentially life threatening skin rashes are often accompanied by flu-like symptoms. The rash may progress to widespread blistering or peeling of the skin. The highest risk for occurrence of serious skin reactions is within the first weeks of treatment. If you have developed exfoliative dermatitis, Stevens-Johnson syndrome or toxic epidermal necrolysis with the use of Salazopyrin Tablets you must not be re -started on Salazopyrin Tablets at any time. If you develop a rash or these skin symptoms, stop taking Salazopyrin Tablets, seek immediate advice from a doctor and tell your doctor that you are taking this medicine. Severe, life-threatening allergic reactions such as Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) have been reported in patients taking various drugs including Salazopyrin Tablets. It is important to note that early signs of severe allergy, such as fever or swollen lymph nodes, may be present even though rash is not evident. If such signs or symptoms are present, you should seek immediate advice from a doctor. Salazopyrin Tablets should be discontinued if an alternative cause for the signs or symptoms cannot be established. Children and adolescents Sulfasalazine is not recommended if you are a child and have systemic -onset juvenile rheumatoid arthritis (Stills disease). Tests on your blood, kidneys, liver and urine Your doctor will be taking blood tests to check your blood, your kidneys before you start treatment and regularly during treatment. They will also measure substances produced by your liver known as enzymes (liver function tests) before you start treatment and at regular intervals. They may also test your urine for protein and blood. Other medicines and Salazopyrin Tablets Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. In particular, the following medicines may interact with Salazopyrin tablets:
Page 3 of 9
Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, you MUST ask your doctor or pharmacist for advice before taking this medicine. You should avoid breast-feeding while taking this medicine. There have been reports of diarrhoea or blood in the stools of babies of breast-feeding mothers taking Salazopyrin tablets. If this happens you must stop taking Salazopyrin Tablets and see your doctor as soon as possible. There have been reports of babies with birth defects of the brain, spine or spinal cord born to mothers who were exposed to sulfasalazine during pregnancy, although the role of sulfasalazine in these defects has not been established. Low sperm count and infertility may occur in men treated with sulfasalazine. Discontinuation of the medicine appears to reverse these effects within 2 to 3 months. Ask your doctor or pharmacist for advice before taking any medicine. Driving and using machines Salazopyrin tablets are unlikely to affect your ability to drive or use machinery.
Salazopyrin Tablets Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. The tablets should be taken with a glass of water and should be swallowed whole. Do not crush , break or chew the tablets. The recommended doses for the following conditions are: For Inflammatory bowel disease: Ulcerative Colitis Adults and the Elderly
Page 4 of 9
Crohn's Disease Adults and the Elderly
4. Possible side effects Like all medicines, this medicine can cause side effects, although not everybody gets them.
Page 5 of 9
Stop taking Salazopyrin Tablets and tell your doctor immediately if you experience any of the following symptoms after taking this medicine. Although they are very rare, these symptoms can be serious.
Page 6 of 9
• • • • • • •
Inflamed mouth (stomatitis) Cough Itching of the skin Purple discolourations on the skin Joint pain Protein in urine Fever
Uncommon (may affect up to 1 in 100 people)
Page 7 of 9
•
Deficiency in folic acid (may cause fatigue)
Very rarely sulfasalazine has caused permanent staining of extended wear soft contact lenses. See section 6. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any
not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Salazopyrin Tablets Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the bottle after EXP. The expiry date refers to the last day of that month. Store your tablets below 25oC in a dry place. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Salazopyrin Tablets contain The active substance is sulfasalazine. Each tablet contains 500 mg of sulfasalazine. Other ingredients are maize starch, PVP (povidone), magnesium stearate, colloidal silicon dioxide. What Salazopyrin Tablets look like and contents of the pack The tablets are yellow in colour, and are round. They have "KPh" imprinted on one side and "101", on the other. The tablets are the colour of the medicine itself. They contain no artificial colouring. Salazopyrin is supplied in bottles. Each bottle contains 112 tablets. Marketing Authorisation Holder and Manufacturer The marketing authorisation for this medicine is held by: Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK. The manufacturer of this medicine is: Recipharm Uppsala AB, Björkgatan 30, Uppsala Domkyrkofors, Uppsala, 753 23, Sweden.
Page 8 of 9
For any information about this medicine, please contact: Medical Information, Pfizer Limited, Walton Oaks, Dorking Road, Tadworth, Surrey, KT20 7NS. Telephone 01304 616161. General Advice Because the tablets are coloured yellow they may cause your urine or motions to become a yellow/orange colour. This is normal and harmless but can stain fabric. Any Salazopyrin soiled fabric should be put in to soak. Difficult stains may be removed with a solution of washing soda. Always test the effect of soda on a small piece of the fabric first. Then apply a mild acid such as white vinegar. Sulfasalazine has caused permanent staining of extended wear soft co ntact lenses. Although this happens very rarely. Daily-wear soft contact lenses and gas permeable lenses respond to standard cleaning if this happens. This leaflet was last revised in 04/2024 Ref: SZ 22_3
Page 9 of 9
Salazopyrin Tablets comes as tablet. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Salazopyrin Tablets is sulfasalazine.
This leaflet reproduces the patient information leaflet approved for Salazopyrin Tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Induction and maintenance of remission of ulcerative colitis; treatment of active Crohn's Disease.
The dose is adjusted according to the severity of the disease and the patient's tolerance to the drug, as detailed below.
Elderly Patients
No special precautions are necessary.
a) Ulcerative colitis
Adults
Severe Attacks
2-4 tablets four times a day may be given in conjunction with steroids as part of an intensive management regime. Rapid passage of the tablets may reduce effect of the drug.
Night-time interval between doses should not exceed 8 hours.
Moderate Attack
2-4 tablets four times a day may be given in conjunction with steroids.
Maintenance Therapy
With induction of remission reduce the dose gradually to 4 tablets per day. This dosage should be continued indefinitely since discontinuance even several years after an acute attack is associated with a four fold increase in risk of relapse.
Paediatric population
The dose is reduced in proportion to body weight.
Acute Attack or Relapse
40-60 mg/kg per day
Maintenance Dosage
20-30 mg/kg per day
Suspension may provide a more flexible dosage form.
b) Crohn's Disease
In active Crohn's Disease, this medicine should be administered as in attacks of ulcerative colitis (see above).
Sulfasalazine is contraindicated in:
Infants under the age of 2 years.
Patients with a known hypersensitivity to sulfasalazine, its metabolites or any of the excipients as well as sufonamides or salicylates.
Patients with porphyria.
Serious infections associated with myelosuppression, including sepsis and pneumonia, have been reported. Patients who develop a new infection while undergoing treatment with sulfasalazine should be monitored closely. Administration of sulfasalazine should be discontinued if a patient develops a serious infection. Caution should be exercised when considering the use of sulfasalazine in patients with a history of recurring or chronic infections or with underlying conditions which may predispose patients to infections.
Complete blood counts, including differential white cell count and liver function tests, should be performed before starting sulfasalazine, and every second week during the first three months of therapy. During the second three months, the same tests should be done once monthly and thereafter once every three months, and as clinically indicated. Baseline assessment of renal function (including urinalysis) is required to be performed in all patients initiating treatment with sulfasalazine. For patients with baseline renal impairment, treatment with sulfasalazine should only be initiated if the benefits are considered to outweigh risk. Thereafter, periodic renal function monitoring, especially in the early months of treatment, should be conducted based on clinical judgment taking baseline renal function into account. Treatment should be discontinued if renal function deteriorates. The patient should also be counselled to report immediately with any sore throat, fever, malaise, pallor, purpura, jaundice or unexpected non-specific illness during sulfasalazine treatment, this may indicate myelosuppression, haemolysis or hepatoxicity. Treatment should be stopped immediately while awaiting the results of blood tests. Please see section 4.4 “Interference with laboratory testing”.
Sulfasalazine should not be given to patients with impaired hepatic function or with blood dyscrasias, unless the potential benefit outweighs the risk.
Sulfasalazine should be given with caution to patients with severe allergy or bronchial asthma.
Severe hypersensitivity reactions may include internal organ involvement, such as hepatitis, nephritis, myocarditis, mononucleosis-like syndrome (i.e., pseudomononucleosis), hematological abnormalities (including hematophagic histiocytosis), and/or pneumonitis including eosinophilic infiltration.
Severe, life-threatening, systemic hypersensitivity reactions such as Drug rash with eosinophilia and systemic symptoms (DRESS) have been reported in patients taking various drugs including sulfasalazine. It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, the patient should be evaluated immediately.
Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of sulfasalazine. Patients appear to be at highest risk for these events early in the course of therapy, the onset of the event occurring in the majority of cases within the first month of treatment.
Sulfasalazine should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.
Sulfasalazine should be discontinued if an alternative etiology for the signs or symptoms cannot be established.
Use in children with the concomitant condition systemic onset juvenile rheumatoid arthritis may result in a serum sickness like reaction; therefore sulfasalazine is not recommended in these patients.
Since sulfasalazine may cause haemolytic anaemia, it should be used with caution in patients with G-6-PD deficiency.
Oral sulfasalazine inhibits the absorption and metabolism of folic acid and may cause folic acid deficiency (see section 4.6), potentially resulting in serious blood disorders (e.g., macrocytosis and pancytopenia), this can be normalised by administration of folic acid or folinic acid (leucovorin).
Because sulfasalazine causes crystalluria and kidney stone formation, adequate fluid intake should be ensured during treatment.
Oligospermia and infertility may occur in men treated with sulfasalazine. Discontinuation of the drug appears to reverse these effects within 2 to 3 months.
Interference with laboratory testing
Several reports of possible interference with measurements, by liquid chromatography, of urinary normetanephrine causing a false-positive test result have been observed in patients exposed to sulfasalazine or its metabolite, mesalamine/ mesalazine.
Sulfasalazine or its metabolites may interfere with ultraviolet absorbance, particularly at 340 nm, and may cause interference with some laboratory assays that use NAD(H) or NADP(H) to measure ultraviolet absorbance around that wavelength. Examples of such assays may include urea, ammonia, LDH, α-HBDH and glucose. It is possible that alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatine kinase-muscle/brain (CK-MB), glutamate dehydrogenase (GLDH), or thyroxine may also show interference when sulfasalazine treatment is given at high doses. Consult with the testing laboratory regarding the methodology used. Caution should be exercised in the interpretation of these laboratory results in patients who are receiving sulfasalazine. Results should be interpreted in conjunction with clinical findings.
Reduced absorption of digoxin, resulting in non-therapeutic serum levels, has been reported when used concomitantly with oral sulfasalazine.
Sulfonamides bear certain chemical similarities to some oral hypoglycemic agents. Hypoglycemia has occurred in patients receiving sulfonamides. Patients receiving sulfasalazine and hypoglycemic agents should be closely monitored.
Due to inhibition of thiopurine methyltransferase by sulfasalazine, bone marrow suppression and leucopenia have been reported when the thiopurine 6-mercaptopurine or it's prodrug, azathioprine, and oral sulfasalazine were used concomitantly.
Coadministration of oral sulfasalazine and methotrexate to rheumatoid arthritis patients did not alter the pharmacokinetic disposition of the drugs. However, an increased incidence of gastrointestinal adverse events, especially nausea, was reported.
Several reports of possible interference with measurements, by liquid chromatography, of urinary normetanephrine causing a false-positive test result have been observed in patients exposed to sulfasalazine or its metabolite, mesalamine/ mesalazine.
Pregnancy
Reproduction studies in rats and rabbits have revealed no evidence of harm to the fetus. Oral sulfasalazine inhibits the absorption and metabolism of folic acid and may cause folic acid deficiency. There have been reports of babies with neural tube defects born to mothers who were exposed to sulfasalazine during pregnancy, although the role of sulfasalazine in these defects has not been established. Because the possibility of harm cannot be completely ruled out, sulfasalazine should be used during pregnancy only if clearly needed.
Breast-feeding
Sulfasalazine and sulfapyridine are found in low levels in breast milk. Patients should avoid breastfeeding while taking this medicine.
There have been reports of bloody stools or diarrhoea in infants who were breastfeeding from mothers on sulfasalazine. In cases where the outcome was reported, bloody stools or diarrhoea resolved in the infant after discontinuation of sulfasalazine in the mother.
Sulfasalazine has no influence on the ability to drive and use machines.
Overall, about 75% of ADRs occur within 3 months of starting therapy, and over 90% by 6 months. Some undesirable effects are dose-dependent and symptoms can often be alleviated by reduction of the dose.
General
Sulfasalazine is split by intestinal bacteria to sulfapyridine and 5-amino salicylate so ADRs to either sulfonamide or salicylate are possible. Patients with slow acetylator status are more likely to experience ADRs related to sulfapyridine. The most commonly encountered ADRs are nausea, headache, rash, loss of appetite and raised temperature.
Specific
The adverse reactions observed during clinical studies conducted with Sulfasalazine have been provided in a single list below by class and frequency (very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1000 to < 1/100); rare (1/10000 to <1/1000); very rare (<1/10000); not known (cannot be estimated from available data)). Where an adverse reaction was seen at different frequencies in clinical studies, it was assigned to the highest frequency reported.
Additional reactions reported from post-marketing experience are included as frequency Not known (cannot be estimated from the available data) in the table below.
MedDRA System Organ Class
Frequency
Adverse Drug Reaction
Infections and Infestations
Not known
aseptic meningitis, pseudomembranous colitis
Blood and lymphatic system disorders
Common
leukopenia
Uncommon
thrombocytopenia**
Not known
agranulocytosis, aplastic anaemia, haemolytic anaemia, heinz body anaemia, hypoprothrombinaemia, lymphadenopathy, macrocytosis, megaloblastic anaemia, methaemoglobinaemina, neutropenia, pancytopenia, pseudomononucleosis**
Immune system disorders
Not known
anaphylaxis*, polyarteritis nodosa, serum sickness
Metabolism and nutrition system disorders
Common
loss of appetite
Not known
folate deficiency**
Psychiatric disorders
Common
insomnia
Uncommon
depression
Not known
hallucinations
Nervous system disorders
Common
dizziness, headache, taste disorders
Uncommon
convulsions
Not known
aseptic meningitis, ataxia, encephalopathy, peripheral neuropathy, smell disorders
Ear and labyrinth disorders
Common
tinnitus
Uncommon
vertigo
Cardiac disorders
Not known
allergic myocarditis**, cyanosis, pericarditis
Vascular disorders
Uncommon
vasculitis
Not known
pallor**
Respiratory, thoracic and mediastinal disorders
Common
cough
Uncommon
dyspnoea
Not known
fibrosing alveolitis, eosinophilic infiltration, interstitial lung disease*, oropharyngeal pain**
Gastrointestinal disorders
Very common
gastric distress, nausea
Common
abdominal pain, diarrhoea*, vomiting*, stomatitis
Not known
aggravation of ulcerative colitis*, pancreatitis, parotitis
Hepatobiliary disorders
Uncommon
jaundice**
Not known
hepatic failure*, hepatitis fulminant*, hepatitis**, hepatitis cholestatic*, cholestasis**
Skin and subcutaneous tissue disorders
Common
pruritus, purpura**
Uncommon
alopecia, urticaria
Not known
drug rash with eosinophilia and systemic symptoms (DRESS)**, epidermal necrolysis (Lyell's syndrome)**, Stevens-Johnson syndrome**, exanthema, exfoliative dermatitis**, angioedema*, toxic pustuloderma, lichen planus, photosensitvity, erythema
Musculoskeletal and connective tissue disorders
Common
arthralgia
Not known
system lupus erythematosus, Sjogren's syndrome
Renal and urinary disorders
Common
proteinuria
Not known
nephrotic syndrome, interstitial nephritis, nephrolithiasis*, haematuria, crystalluria**
Reproductive system and breast disorders
Not known
reversible oligospermia**
General disorders and administration site conditions
Common
fever
Uncommon
facial edema
Not known
yellow discoloration of skin and body fluids*
Investigations
Uncommon
elevation of liver enzymes
Not known
induction of autoantibodies
Frequency categories: Very common ≥1/10; Common ≥1/100 to <1/10; Uncommon ≥1/1000 to <1/100; Rare ≥1/10000 to <1/1000; Very rare <1/10000; Not known (cannot be estimated from available data)
* ADR identified post-marketing
** see section 4.4 Special warnings and precautions for use
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
The drug has low acute per oral toxicity in the absence of hypersensitivity. There is no specific antidote and treatment should be supportive.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Medicines sold in Poland with the same active substance: W Polsce znany jako
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Salazopyrin Tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.